Novel Fusion Protein (Preclinical Drug) Equipment
-
based in SOUTH KOREA
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures its safety in GLP toxicity ...
-
Manufactured by Cartherics Pty ltdbased in AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
-
based in IRELAND
Exclusive collaboration to develop novel, multi-specific fusion protein based therapies for autoimmune and inflammatory ...
-
Manufactured by Ocugen, Inc.based in USA
OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD). Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you